DOCSLIB.ORG

Approval Has Been Given for the Following Antibiotics Preparations to Be Imported Into Trinidad and Tobago

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Approval Has Been Given for the Following Antibiotics Preparations to Be Imported Into Trinidad and Tobago LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaHairs.gov.tt 12 Chap. 30:02 Antibiotics SUBSIDIARY LEGISLATION *IMPORTATION OF ANTIBIOTICS PREPARATIONS ORDER made under section 5 Approval has been given for the following antibiotics preparations to be imported into Trinidad and Tobago: 52/1967. Maurry Biological Co., 6109S, Western Avenue , Los Angeles 47, California, U.S.A Alycillin (Procuin Penicillin G. U.S.P. and Streptomycin Sulphate, U.S.P.) Carlo Erba, S.PA,Milano, Italy. Tetralysal Capsu les 150 mgm , (contg: Lymecyeline i.e., tetracycline- L-methylenelysme) Tetralysal Ampoules IN. (lOO-mg:m. and 200-mgm.) Mebinot Complex Tablets (contg: Streptomycin Sulpliate) Emero-Ptrtsttna Syrup (contg. Dihydrosucptomyciu) Frank W. Homer Ltd., Montreal 3, Canada. P-50 Liquid (contg: Penicillin G. Potassium) P-50 Tablets (contg: Penicillin G. Potassium) Therapliarm Ltd., 86A, Richmond Road, Kingston-on-Thames , Surrey, England. Neolate Polyantibiotic Dusting Powder (contg: Neomycin and Zinc Bacitracin) Neolate Polyantibiotic Dusting Powder with amino -acids (contg: Neomycin and Gramicidin) Diplomycin Dusting Powder (contg: Zinc Bacitracin and Polymyxin B. Sulphate) Trimycin Dusting Powder (contg: Neomycin Sulpliate, Zinc Bacitracin and Polymyxin B. Sulpliate) Neomycin Dusting Powder (contg: Neomycin Sulphate) Bristol Laboratories, Syracuse, New York, U.S.A Versapen Capsules 250-mg:m. (contg: Hetacillin) Versapen Powder for Oral Suspension (contg: Hetacillin) * See Note on page 2. UPDATED TO DECEMBER 31ST 2009 LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaffairs.gov.tt Antibiotics Chap. 30:02 13 Imporuuto n ojAnuhtoucs Preparauons Order [Subsidiary] Marsing & Co. Ltd., Copenhagen, Denmark. Marco/Synbiotic Injection [contg: N-(pyno-Iidino-methyl) tetracycline­ cIiIoramplienicol-succinate] Marco/Synbiotic Capsules (Tetracycline and CIiIoramphenicol) Marcotycin (Oxytetracycline) Boots Pure Drug Co. Ltd., Station Street, Nottingham, England. Nivebaxin (antibiotic/amino-acid Powder) AIIergan Pharmaceuticals Ltd., 1000, South Grand Avenue, Santa Ana, California, U.S.A Predinycin (contg: Neomycin Sulphate) Predinycin P. (contg:Polymyxin B. Sulp. and Sulphate) Coujuuctiu (coutg. Polyiuyxiu B. Su11Jl.LaLt: and Neoutyciu Sulphate) Cyanamid G.M.B.H., Fritz Mintz Strasser, Municli, Germany 139/1969. Ledermix Bristol Laboratories Division of Bristol Meyers Co. of Syracuse , NY, U.S.A. - through Bristol Laboratories Int., U.S.A ., Colon, Republic of Panama. "Tetrex" bid Caps. 500-mgm. Fujisawa Pharmaceutical Co. Ltd., 3, Doshomachi, 4-Chrome, Osaka, Japan. Trichomycin Oral Tablets Trichomycin Vaginal Tablets Tli chomycln OInurrent Consolidated Chemical Ltd. The Industtial Estate, Wrexham , Denbighshire, North Wales, England. Enteromide Otottips Ear Drops Uromide Norma Chemicals Ltd., 198, Finchley Road, London, N.W.3. Polynorm Ointment A/S Dumex Limited, Copenhagen, Denmark. CIiIoramex Capsules 250-mgm. CIiIoramex Fort Capsules 250-mgm . Pfizer Limited, Bombay, India. Terramycin Capsules 250-mgm. Terramycin Syrup 60-cc. 125-mgm./5-cc. Tetracyn Capsules 250-mgm. Tctrucyn I.M. Injection lOO-mgm. Tetracyn I. V Injection 250-mgm. L.R.o. UPDATED TO DECEMBER 31ST 2009 LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaHairs.gov.tt 14 Chap. 30:02 Antibiotics [Subsidiary] Imporuuion ojAnuhtoucs Preparauons Order 16811967. Leo Pharmaceutical Products, Ballerup, Denmark. Diaron Leo Tablets Berk Pharmaceuticals Ltd., Cattleshall Lane, Godalming, Suney, England. Berkmycen Tablets 250-mgm. Tetravet The Veterinary Corporation of America, 111-115, Park Avenue, Summit, N.J., U S.A Vetconnycin 25 Soluble Powder Vetcormycin Soluble Powder 59/1968. Mesco Laboratories Ltd., 6, Broad Street Place, London, E.C.2. Mcacocillin Injection x 1-gm. Mescocillin Injection x 0.25 gm. Mescocillin Injection x 0.2 gm, Mescostrep Injection Mesdidro Injection Mesbillin Injection Penocaine Inj ection Penocaine Forte Injection 2,OOO,OOO-1.u. Penocaine Forte Injection 300,000 units Penicillin Buffered Penirnycetin Injection Mesdistrep Injection Mescomycetin Capsules Mescomycetin Palmitate Syrup Mesvitacyn Capsules Mesvitacyn Palmitate Syrup Mestrepcetin Capsules Mescol Capsules Mescolone witb Neomycin Ophtbalmic Ointment Chlortetcine Capsules Mcatracyclinc Capaulca Mescoteracyn Capsules Mescrine Capsules Mescrine Tablets Escovicetin Capsules Camden Chemical Co. Ltd., 61, Gray's Inn Road, London, WC.!. Tampovagan PS.S Pessaries Tampovagan 'N' Pessaries UPDATED TO DECEMBER 31ST 2009 LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaffairs.gov.tt Antibiotics Chap. 30:02 15 Imporuuto n ojAnuhtoucs Preparauons Order [Subsidiary] Beecham Research Laboratories, Brentford,Middlesex, England. 111/1968. Veracillin Capsules 125 mgm. Veracillin Syrup 62.5 mgm./5 ml. Veracillin in 60-mil. phials Veracillin Suspension 62.5 mgm./5ml. in 6O-mil. phials Glaxo Laboratories Ltd., of Greenford, England - through Glaxo-Allenburys (Export) Ltd., 106, High Holborn, London, W.CI. Crystapen G. Syrup 125mgm./5ml. in 100-mil. phials Crysrapen G. Syrup 250 mgm.lSml. ill too-mil . phials Warner-Chilcott Laboratories, Division of Warner Lambert Pharmaceutical Co., Morris Plains, N.J., U.S.A. Coly-Mycin M Injectable lSO-mgm. (Sodium Colistimetbate for inj ection) Coly-Mycin S Otic , 5-mil. (witb Neomycin and Hydrocortisone) Coly. My cin S Otic, 1(Lrnil (with Neomycin and Hydrocortisone) Coly-Mycin S Pediatric (Colistin Sulphate for Oral Suspension) 300-mgm.l70-mil. Dumex Ltd" Copenhagen, Denmark-c-through Ayrton Saunders & Co" Ltd" 34, Hanover Street, Liverpool 1, Lancashire, England. Dtnnocycline Capsules Dtnnocycline Syrup Dtnnocycline Drops Dtnnocycline 3% Topical Ointment Dtnnocycline Eye Ointment Stoptomcx Fortified Tetrabiocin Schering Corporation Ltd ., 3535, Trans-Canada Highway, Pointe Claire, Quebecc-through Schciiug Trausauierica Corp. , Colon, R.P. Depot, Apt 949, Colon Free Zone, Rep. de Panama. Garamycin Cream Garamycin Ointment Garamycin Injection (40 mgm. Gentamicin Sulphate/mil.) Farbwerke Hoechsr An , Gerrn ~ny Hostacycline ' P' 500 Capsules 500-mgm. Carlisle Laboratories Ltd., 48, Tudor Street, Bridgetown, Barbados. Benapen V. Granules for Suspension Carlocort Topical Ointment L.R.o. UPDATED TO DECEMBER 31ST 2009 LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaHairs.gov.tt 16 Chap. 30:02 Antibiotics [Subsidiary] Imporuuion ojAnuhtoucs Preparauons Order Mowatt & Moore Ltd., Montreal, Canada. Pensitabs (Penicillin Tablets, B.P.) 5oo,000-i.u. Crystalline Penicillin G-Potassium per tablet Tetracaps Capsules 250-mgm. x 12 Tetracaps Capsules 250-mgm. x 100 Tetracaps Suspension 125-mgm.l5cc. in 60-cc. phials Sopar, Brussels, Belgium . Sopacycline Capsules Sopacycline Oral Suspension Parcycline Pediatric Drops Pigot & Smith Ltd. , Leigh Street, Wigen, Lancashire, england. Trisep Aerosol Disbiotic Aerosol Dispray Aerosol Allen & Hanburys Ltd., Bethnal Green, London, E,2., England. Propaderm A Ointment G. D. Searle & Co. Ltd., Lane End Road, High Wycombe. Bucks., England. Lomotil with Neomycin Tablets (each tablet containing diphenoxylate hydrochloride 2Smg., neomycin sulphate B.P 250-mg. and atropine sulphate, 0.025 mg.) 17011 968. Riker Laboratories, Morley Street, Loughborough, England. Rikospray Fison's Limited, 9, Grosvenor Street, London, W.1. Sterispray Steritulle Ayrton Saunders & Co. Ltd., Hanover Street, Liverpool, England. Pulv, Penicillin et Sulphathiazole 5000-units/gm. Allen & Hanbury's Limited, Bethnal Green, London, Wj., England. Propaderm N Cream 5 mgm.lgm. Propaderm N Ointment 5 mgm.lgm . Pfizer Limited, England. Vibramycin Capsules 100 mgm. Vibramycin Capsules "0 mgm Vibramycin Syrup. UPDATED TO DECEMBER 31ST 2009 LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaffairs.gov.tt Antibiotics Chap. 30:02 17 Imporuuton ojAnuhtoucs Preparauons Order [Subsidiary] E. R Squibb & Sons , Inc., New York. 180/1968 . Fungizone Intravenous 50~mgm. Kenalog-S Ophthalmic Ointment 3 . 6 ~ gm . Mycostatin Cream 15 ~ gm . Mycostatin Topical Powder 15 ~gm. Pentids ''400'' for Syrup Pentids '1+00" Tablets Pentids "800" Tablets E. R Squibb & Sons , Montreal, Canada. Kenacomb Mild Ointment 0.025% Kenacomb Mild Cream 0.025% Lifepharma, Milan, Italy Chlortetracycline (Lifechlorine) Capsules 250 mgm. B.P/NF Chlortetracycline Oral Suspension 125 mgm./5 cc. B.PC 2, 4, & 1 6 ~ oz. Chlortetracycline Pediatric Drops 100 mgm./lO cc. IO's Chlortetracycline Dispersible Powder 50 mgm.S 8.m. chocolate Mixture FS. bats. 50 gm. & 75 gm, Chlortetracycline Ear Drops 0.5% 10 cc. B.P C Chlortetracycline Eye Drops 0.5% 10 cc. B.P.C Chlortetracycline Bye OiUlIIlt:IlL1%, 1s-0Z. LUO t: B.P.C. Chlortetracycline Skin Ointment 3% , Y:~oz . tube B.P.C Cycloserine Capsules 250 ~mgm . B.P Demethylchlortetracycline (Demechloryn) Capsules 150 mgm. B.P Demethylchlortetracycline Oral Suspension 75 mgm./5cc. B.PC 2,4, and Io -fl. oz. Demethylchlortetracycline Pediatric Drops, 60 mgm.!cc. X 10 cc. B.P.C. Erythromycin (Liferythrynj'Tablets 100 mgm BP/US.P. Erythromycin (Liferythryn)Tablets 250 mgm. BP/U,S.P. Erythromycin Eye Ointment 1% 5 ~ gm . tubes FS. Erythromycin Skin Ointment 3% 15 ~ gm . tubes FS. Brytlutnuyciu Bstolate Capsules 250~lllglll . B .P. Kanamycin Sulphate (Lifekimamyn) Injections l -gm, phials B.P C./USP Novobiocin (Lifebiocin) Tablets or Capsules 250~mgm. B.P/u'S.P Novobiocin-Tetracycline Association (Novotetra)Tablets Oxytetracycline (Lifeoxyne) Tablets 100 mgm. sugar-coated, B.P (or capsules B.P C./N .F.) Oxytetracycline Tablets
Load more

Recommended publications
  • Derivatives of Clavulanic Acid, Process for Their Preparation And
    Europaisches Patentamt © ê European Patent Office © Publication number: 0 003 254 Office européen des brevets Bl © EUROPEAN PATENT SPECIFICATION (45) Date of publication of patent spécification: 28.03.84 © Int. ci.3: C 07 D 498/04, A 61 K 31/42, @ Application number: 78300762.8 A 61 K 31/43, @ Date offiling: 07.12.78 A 61 K 31/545 //(C07D498/04, 263/00, 205/00), (A6 1 K3 1 /43, 3 1/42), (A61K3 1/545, 31/42) (54) Derivatives of clavulanic acid, process for their préparation and compositions containing them. (§) Priority: 26.01 .78 GB 312978 @ Proprietor: BEECHAM GROUP PLC Beecham House Great West Road Brentford Middlesex (GB) (43) Date of publication of application: 08.08.79 Bulletin 79/1 6 @ Inventor: Gasson, Brian Charles 9, Clarence Walk (45) Publication of the grant of the patent: Redhill Surrey (GB) 28.03.84 Bulletin 84/13 © Représentative: Hesketh, Alan, Dr. et al, (84) Designated Contracting States: European Patent Attorney Beecham BE CH DEFRGBITNL Pharmaceuticals Great Burgh Yew Tree Bottom Road Epsom, Surrey, KT18 5XQ (GB) (56) Références cited: BE - A - 847 046 The file contains technical information submitted after the application was filed and not included in this spécification Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid.
    [Show full text]
  • 1028 Subpart A—Susceptibility Discs
    § 460.1 21 CFR Ch. I (4±1±96 Edition) 460.137 Methicillin concentrated stock solu- Neomycin: 30 mcg. tions for use in antimicrobial suscepti- Novobiocin: 30 mcg. bility test panels. Oleandomycin: 15 mcg. 460.140 Penicillin G concentrated stock so- Penicillin G: 10 units. lutions for use in antimicrobial suscepti- Polymyxin B: 300 units. bility test panels. Rifampin: 5 mcg. 460.146 Tetracycline concentrated stock so- Streptomycin: 10 mcg. lutions for use in antimicrobial suscepti- Tetracycline: 30 mcg. bility test panels. Tobramycin: 10 mcg. 460.149 Tobramycin concentrated stock so- Vancomycin: 30 mcg. lutions for use in antimicrobial suscepti- bility test panels. The standard discs used to determine 460.152 Trimethoprim concentrated stock the potency shall be made of paper as solutions for use in antimicrobial suscep- described in § 460.6(d). Each antibiotic tibility test panels. compound used to impregnate such 460.153 Sulfamethoxazole concentrated stock solutions for use in antimicrobial standard discs shall be equilibrated in susceptibility test panels. terms of the working standard des- ignated by the Commissioner for use in AUTHORITY: Sec. 507 of the Federal Food, determining the potency or purity of Drug, and Cosmetic Act (21 U.S.C. 357). such antibiotic. SOURCE: 39 FR 19181, May 30, 1974, unless (b) Packaging. The immediate con- otherwise noted. tainer shall be a tight container as de- fined by the U.S.P. and shall be of such Subpart AÐSusceptibility Discs composition as will not cause any change in the strength, quality, or pu- § 460.1 Certification procedures for an- rity of the contents beyond any limit tibiotic susceptibility discs.
    [Show full text]
  • WO 2010/025328 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 March 2010 (04.03.2010) WO 2010/025328 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US2009/055306 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 28 August 2009 (28.08.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/092,497 28 August 2008 (28.08.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): FOR¬ GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, EST LABORATORIES HOLDINGS LIMITED [IE/ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, —]; 18 Parliament Street, Milner House, Hamilton, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Bermuda HM12 (BM).
    [Show full text]
  • Evaluating Risks from Antibacterial Medication Therapy
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations Summer 2010 Evaluating Risks from Antibacterial Medication Therapy Sharon B. Meropol University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Therapeutics Commons Recommended Citation Meropol, Sharon B., "Evaluating Risks from Antibacterial Medication Therapy" (2010). Publicly Accessible Penn Dissertations. 424. https://repository.upenn.edu/edissertations/424 A version of Chapter 3 has been published: Meropol SB, Chen Z, Metlay JP. Reduced antibiotic use for acute respiratory infections in adults and children. Br J Gen Prac. Oct. 2009; 59(567)3321-328.DOI:10.3399/ bjgp09X472610. E321-328 PMID: 19843412 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/424 For more information, please contact [email protected]. Evaluating Risks from Antibacterial Medication Therapy Abstract ABSTRACT EVALUATING RISKS FROM ANTIBACTERIAL MEDICATION THERAPY USING AN OBSERVATIONAL PRIMARY CARE DATABASE Sharon B. Meropol Joshua P. Metlay Virtually everyone in the U.S. is exposed to antibacterial drugs at some point in their lives. It is important to understand the benefits and risks elatedr to these medications with nearly universal public exposure. Most information on antibacterial drug-associated adverse events comes from spontaneous reports. Without an unexposed control group, it is impossible to know the real risks for treated vs. untreated patients. We used an electronic medical record database to select a cohort of office visits for non-bacterial acuteespir r atory tract infections (excluding patients with pneumonia, sinusitis, or acute exacerbations of chronic bronchitis), and compared outcomes of antibacterial drug-exposed vs.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Interest in the Physical, Chemical and Spectroscopic Properties of the P
    VOL. XXVII NO. 3 THE JOURNAL OF ANTIBIOTICS 215 A CHIROPTICAL STUDY OF PENICILLINS L. A MITSCHER, PETER W. HOWISON* and THEODORE D. SOKOLOSKI Division of Natural Products Chemistry The Ohio State University, Columbus, Ohio 43210. U.S. A. (Received for publication November 9, 1973) ORD and CD spectra are reported for a series of penicillin antibiotics and related degradation products. The results, when compared with published X-ray data, suggest that some conformational changes can apparently go undetected by chiroptical techniques in this series and that the side chain substituent at C6 plays a relatively minor role in determining the sign and intensity of the COTTON effect unless its stereochemistry is inverted. The rather large spectroscopic effect following Ca epimerization has potential for development as an assay for the percentage of 6-epihetacillin in a given mixture. Some preliminary data are presented showing the utility of this method for investigating the kinetics of CB epimerization. Semiempirical predictive rules developed for simple amides are inadequate for rationalizing the penicillin spectra. The origin of the COTTON effects is briefly discussed and contrasted with the cephalosporin antibiotics. Interest in the physical, chemical and spectroscopic properties of the p-lactam antibiotics remains high because of their outstanding clinical utility and a desire to rationalize their mode of action on a molecular level. A recent review volume has collected much of this scattered information1). One of the techniques which has found wide application for the study of the stereo-chemistry and solution conformation of antibiotics is optical rotatory dispersion and circular dichroism spectroscopy2). Although CD measurements of the cephalosporins have been discussed 3,4) no corresponding study of the chiroptical properties of the penicillins has yet appeared except in brief extracts'.
    [Show full text]
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units
    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
    [Show full text]
  • FOR YOUR INFORMATION L I T a Mold Problem in 1972-73 Feed Grains Recognized As a Serious Problem by Various State Gibberella Zeae and Federal Agencies
    r 1 Association Practitioners; Bovine open ofdistribution. access American Copyright © FOR YOUR INFORMATION L i t A Mold Problem in 1972-73 Feed Grains recognized as a serious problem by various state Gibberella Zeae and federal agencies. Research has been conducted What is it? largely by university personnel. Mycotoxins in Gibberella zeae is a mold (Fusarium roseum) grains should be recognized as emerging diseases found on com and some other field grains. It is a and of growing importance. The cold, wet growing naturally occurring fungus that is a serious problem season of 1972 was ideal for the production of during a wet, cold growing season and harvesting Fusarium mycoses. The delayed harvest contri­ period such as was experienced in 1972. The buted to the problem. Shortage of natural gas greatest problem areas in 1972 seem to be in made it more difficult to dry com. Normally, corn Southern Michigan, Northwestern Ohio, and is dried to 14% moisture. Much of this year’s com Northern Indiana — but reports indicate lesser had moisture levels ranging from 20 to 35%. contamination in a number of other corn- Twenty-three percent moisture has been recog­ producing states. nized as the minimal moisture level where Fusaria What are its effects? mycotoxin activity occurs. Three known factors produced by this mold What Treatment is Available? cause feeding problems to animals consuming it. Producers of Gibberella zeae contaminated com The “refusal factor” — animals refusing to eat it — have very little means available to reduce the the “emetic factor” — vomiting — are present in problem. Both the emetic and refusal factors are the contaminated grain, and result in reduced very stable to pH changes (pH 2.0-11.0) and to nutrition.
    [Show full text]
  • Antibiotics and Antibiotic Resistance
    This is a free sample of content from Antibiotics and Antibiotic Resistance. Click here for more information on how to buy the book. Index A Antifolates. See also specific drugs AAC(60)-Ib-cr, 185 novel compounds, 378–379 ACHN-975 overview, 373–374 clinical studies, 163–164 resistance mechanisms medicinal chemistry, 166 sulfamethoxazole, 378 structure, 162 trimethoprim, 374–378 AcrAB-TolC, 180 Apramycin, structure, 230 AcrD, 236 Arbekacin, 237–238 AdeRS, 257 Avibactam, structure, 38 AFN-1252 Azithromycin mechanism of action, 148, 153 resistance, 291, 295 resistance, 153 structure, 272 structure, 149 Aztreonam, structure, 36 AIM-1, 74 Amicoumacin A, 222 Amikacin B indications, 240 BaeSR, 257 structure, 230 BAL30072, 36 synthesis, 4 BB-78495, 162 Aminoglycosides. See also specific drugs BC-3205, 341, 344 historical perspective, 229–230 BC-7013, 341, 344 indications, 239–241 b-Lactamase. See also specific enzymes mechanism of action, 232 classification novel drugs, 237 class A, 67–71 pharmacodynamics, 238–239 class B, 69–74 pharmacokinetics, 238–239 class C, 69, 74 resistance mechanisms class D, 70, 74–77 aminoglycoside-modifying enzymes evolution of antibiotic resistance, 4 acetyltransferases, 233–235 historical perspective, 67 nucleotidyltransferases, 235 inhibitors phosphotransferases, 235 overview, 37–39 efflux-mediated resistance, 236 structures, 38 molecular epidemiology, 236–237 nomenclature, 67 overview, 17, 233 b-Lactams. See also specific classes and antibiotics ribosomal RNA modifications, 235–236 Enterococcus faecium–resistancemechanisms,
    [Show full text]
  • Colorado State University Veterinary Diagnostic Laboratories
    Colorado State University Veterinary Diagnostic Laboratories Volume 2, Number 1 Fall 1997 OLetter from the Director Here is issue #3 of LabLines! Inside, you’ll find informative articles on Clostridial perfringens genotyping, Malignant Catarrhal Fever, antimicrobial susceptibility testing, assessing Vitamin A and E status in food animals, blue green algae poisoning, soft tissue sarcomas in dogs and cats, and polioencephalomalacia. Additional stories include Nematodirus in calves, sunburn, agalactia and salt poisoning in swine, and mysterious encephalitis in captive elk. In the last few months, you may have noted a new name on your pathology reports -- Gary Mason. Dr. Mason, a Colorado native, is our new pathologist. He received his DVM from Texas A&M in 1988, and completed his pathology training at the University of Tennessee in 1997. His specialties include cattle pathology, dermatopathology, and a recent interest in fish pathology! We are very pleased to have him join us. In the office area, you may have spoken to our new phone receptionist, Jennifer Swenson. We welcome Nancy Ault back to the office after a summer of maternity leave. We also have two new word processors, Esta Moutoux and Tracie Trimarco, to get your reports to you faster. Additions to laboratory services include: ! Preliminary fax results for biopsies allowing 24-48 hour turnaround time. ! New atomic absorption spectrophotometer allowing new tests in the chemistry/toxicology section. ! New antimicrobial susceptibility testing system. ! On-going test development in the microbiology section. This summer, I participated in the CVMA tour with Jim Noone (CVMA President) and Joe Lory (CVMA Executive Director). It was truly pleasurable to travel through Colorado and meet many of you in person, after years of seeing your names on laboratory requests or visiting with you by phone.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from Treatment of stable chronic obstructive pulmonary disease: a protocol for a systematic review and evidence map Journal: BMJ Open ManuscriptFor ID peerbmjopen-2018-027935 review only Article Type: Protocol Date Submitted by the 15-Nov-2018 Author: Complete List of Authors: Dobler, Claudia; Mayo Clinic, Evidence-Based Practice Center, Robert D.
    [Show full text]
  • Concept Paper
    Concept Paper: Potential Approach for Ranking of Antimicrobial Drugs According to Their Importance in Human Medicine: A Risk Management Tool for Antimicrobial New Animal Drugs Introduction This concept paper discusses a potential approach to considering the human medical importance of antimicrobial drugs when assessing and managing antimicrobial resistance risks associated with the use of antimicrobial drugs in animals. In 2003, FDA established a list ranking antimicrobial drugs according to their relative importance in human medicine primarily for the purpose of supporting a qualitative risk assessment process outlined in agency guidance. It was envisioned by the Agency at the time the current medical importance rankings list was published that it would periodically reassess the rankings to align with contemporary science and current human clinical practices. To that end, this paper describes a potential revised process for ranking antimicrobial drugs according to their relative importance in human medicine, potential revised criteria to determine the medical importance rankings, and the list of antimicrobial drug medical importance rankings that would result if those criteria were to be used. Disclaimer: This concept paper is for discussion purposes only. The intent of this concept paper is to obtain public comment and early input on a potential approach to consider the human medical importance of antimicrobial drugs when assessing and managing antimicrobial resistance risks associated with the use of antimicrobial drugs in animals. This concept paper does not contain recommendations and does not constitute draft or final guidance by the Food and Drug Administration. It should not be used for any purpose other than to facilitate public comment.
    [Show full text]